Method for reducing side effects of CB
View Patent ↗The present application describes a method of treating pain with a combination of a CB 2 cannabinoid receptor agonist and rimonabast.
1. A method for treating a subject suffering from pain using a combination therapy comprising administering a selective CB 2 receptor agonist selected from the group consisting of (Z)—N-(5-tert-butyl-3-butylthiazol-2(3H)-ylidene)-5-chloro-2-methoxybenzamide and (Z)—N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropanecarboxamide in an amount effective to obtain a therapeutic effect, and rimonabant in an amount effective to block any adverse effects mediated by the CB 1 receptor, but not to antagonize the therapeutic effect of the CB 2 receptor agonist.
2. The method of claim 1 wherein the pain is selected from the group comprising neuropathic pain, nociceptive pain, and inflammatory pain.
3. The combination therapy of claim 1 , wherein the CB 2 receptor agonist and the rimonabant are administered as separate pharmaceutical compositions including a pharmaceutically acceptable carrier.
4. The combination therapy of claim 1 , wherein the CB 2 receptor agonist and the rimonabant are administered together as one pharmaceutical composition including a pharmaceutically acceptable carrier.
5. A composition comprising a selective CB 2 receptor agonist selected from the group consisting of (Z)—N-(5-tert-butyl-3-butylthiazol-2(3H)-ylidene)-5-chloro-2-methoxybenzamide and (Z)—N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropanecarboxamide in an amount effective to produce a therapeutic effect, rimonabant in an amount effective to antagonize side and adverse effects produced by the CB 2 agonist, but not to antagonize the therapeutic effect of the CB 2 agonist, and a pharmaceutically acceptable carrier.